Skip to main content
SpringerLink
Log in

Histological, Immunophenotypic and Histomorphometric Characterization of Prostate Cancer Bone Metastases

  • Chapter
The Biology of Skeletal Metastases

Part of the book series: Cancer Treatment and Research ((CTAR,volume 118))

Abstract

Carcinoma of the prostate (CaP) is the most common malignancy in older men in the United States. In 2002, more than 200,000 cases of CaP were diagnosed and an estimated 32,000 Americans died of this cancer (Jemal et al., 2002). Most of the devastating effects of prostate cancer can be attributed to its tendency to metastasize to bone. At the time of clinical presentation, 8% of Caucasian-Americans and 14% of African-Americans already have bone metastasis (Coffey, 1993; Whitmore, 1990), and bone metastases will develop in the majority of patients with recurrent hormoneindependent CaP. Bone metastases are a major cause of morbidity in patients with advanced CaP; major clinical features of bone metastases are intractable bone pain, fracture, spinal cord compression and eventually wasting and death. While the biology of the primary tumor has been intensively studied, the special aspects of CaP bone metastases that lead to abnormal bone growth not ordinarily seen in any other cancers are not extensively documented in the literature. In this chapter, we review the detection of CaP metastases, the predilection of CaP to spread to bone, the main phenotypic features of CaP in bone, and the characterization of the histological “osteoblastic” bone response. We conclude with a brief description of our osteoblastic xenograft model and comparison of this model to clinical bone metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abrahamsson, P.A. (1999) Neuroendocrine cells in tumour growth of the prostate. Endocrinerelated Cancer, 6, 503–519.

    Article  CAS  Google Scholar 

  • Allen, F.J., Van Velden, D.J. and Heyns, C.F. (1995) Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer? British Journal of Urology, 75, 751–754.

    Article  PubMed  CAS  Google Scholar 

  • Assikis, V.J., Elgamal, A., Tu, S.M., Daliani, D., Pagliaro, L., Logothetis, C. and Papandreou, C. (2002) Immonotherapy for androgen independent prostate cancer: Results of a Phase I trial with a tumor vaccine of autologous dendritic cells loaded with r-PSMA (DCVaxProstate). Proceedings of the American Association for Cancer Research, 42, 676, #3352.

    Google Scholar 

  • Balk, S.P. (2002) Androgen receptor as a target in androgen-independent prostate cancer. Urology, 60, 132–138.

    Article  PubMed  Google Scholar 

  • Berges, R.R., Vukanovic, J., Epstein, J.I., CarMichel, M., Cisek, L., Johnson, D.E., Veltri, R.W., Walsh, P.C. and Isaacs, J.T. (1995) Implication of cell kinetic changes during the progression of human prostatic cancer. Clinical Cancer Research, 1, 473–480.

    PubMed  CAS  Google Scholar 

  • Bohrer, M.H. and Schmoll, J. (1993) [Immunohistochemical and morphometric studies on neuroendocrine differentiation of prostate carcinomas]. Verhandlungen der Deutschen Gesellschaft fur Pathologie, 77, 107–110.

    PubMed  CAS  Google Scholar 

  • Brown, R.S., Edwards, J., Dogan, A., Payne, H., Harland, S.J., Bartlett, J.M. and Masters, J.R. (2002) Amplification of the androgen receptor gene in bone metastases from hormonerefractory prostate cancer. Journal of Pathology, 198, 237–244.

    Article  PubMed  CAS  Google Scholar 

  • Burki, F., Coindre, J.M. and Mauriac, L. (1987) Sclerotic bone metastases of prostatic origin and osteomalacia. Importance of a histomorphometry study. Progress in Clinical and Biological Research, 243A, 569–571.

    PubMed  CAS  Google Scholar 

  • Byar, D. (1977) VACURG Studies on Prostatic Cancer and its Treatment. Urologic Pathology: The prostate. Tannenbaum M, Editor, Lea and Febiger, Philadelphia, 241–263.

    Google Scholar 

  • Carlier, D. (1903) Les metastases osseuses dans le cancer de la prostate. L’ Echo médical du Nord, 313–324.

    Google Scholar 

  • Carrasquillo, J.A., Whatley, M., Dyer, V., Figg, W.D. and Dahut, W. (2001) Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning. Journal of Nuclear Medicine, 42, 1359–1363.

    PubMed  CAS  Google Scholar 

  • Chang, S.S., Gaudin, P.B., Reuter, V.E., O’Keefe, D.S., Bacich, D.J. and Heston, W.D. (1999) Prostate-specific membrane antigen: much more than a prostate cancer arker. Molecular Urology, 3, 313–320.

    PubMed  CAS  Google Scholar 

  • Charhon, S.A., Chapuy, M.C., Delvin, E.E., Valentin-Opran, A., Edouard, C.M. and Meunier, P.J. (1983) Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer, 51, 918–924.

    Article  PubMed  CAS  Google Scholar 

  • Cheville, J.C., Tindall, D., Boelter, C., Jenkins, R., Lohse, CM., Pankratz, V.S., Sebo, T.J., Davis, B. and Blute, M.L. (2002) Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer, 95, 1028–1036.

    Article  PubMed  Google Scholar 

  • Clarke, N.W., McClure, J. and George, N.J. (1991a) Morphometric evidence for bone resorption and replacement in prostate cancer. British Journal of Urology, 68, 74–80.

    Article  PubMed  CAS  Google Scholar 

  • Clarke, N.W., McClure, J. and George, N.J. (1993) The effects of orchidectomy on skeletal metabolism in metastatic prostate cancer. Scandinavian Journal of Urology and Nephrology, 27, 475–483.

    Article  PubMed  CAS  Google Scholar 

  • Coffey, D.S. (1993) Prostate cancer. An overview of an increasing dilemma. Cancer, 71, 880–886.

    Article  PubMed  CAS  Google Scholar 

  • Cohen, R.J., Glezerson, G. and Haffejee, Z. (1991) Neuro-endocrine cells-a new prognostic parameter in prostate cancer. British Journal of Urology, 68, 258–262.

    Article  PubMed  CAS  Google Scholar 

  • Coindre, J.M., Mage, P., Bui, B.N., Goussot, J.F., De, M.I., De, M.A. and Trojani, M. (1985) Prostatic osteocondensing metastases and osteomalacia. Value of histomorphometric study. Preliminary results. Presse Médicale, 14, 1823–1827.

    CAS  Google Scholar 

  • Corey, E., Quinn, J.E., Bladou, F., Brown, L.G., Roudier, M.P., Brown, J.M., Buhler, K.R. and Vessella, R.L. (2002a) Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. The Prostate, 52, 20–33.

    Article  PubMed  Google Scholar 

  • Corey, E., Brown, L.G., Quinn, J.E., Poot, M., Roudier M.P, Higano, C.S. and Vessella R.L. (2002b) Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clinical Cancer Research, 9, 295–306.

    Google Scholar 

  • Darson, M.F., Pacelli, A., Roche, P., Rittenhouse, H.G., Wolfert, R.L., Young, C.Y., Klee, G.G., Tindall, D.J. and Bostwick, D.G. (1997) Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology, 49, 857–862.

    Article  PubMed  CAS  Google Scholar 

  • de 1a Monte, S.M., Moore, G.W. and Hutchins, G.M. (1986) Metastatic behavior of prostate cancer. Cluster analysis of patterns with respect to estrogen treatment. Cancer, 58, 985–993.

    Article  Google Scholar 

  • Elgamal, A.A., Troychak, M.J. and Murphy, G.P. (1998) ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. The Prostate, 37, 261–269.

    Article  PubMed  CAS  Google Scholar 

  • Fitton, A. and McTavish, D. (1991) Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs, 41, 289–318.

    Article  PubMed  CAS  Google Scholar 

  • Furuya, Y., Akakura, K., Tobe, T., Ichikawa, T., Igarashi, T. and Ito, H. (2001) Prognostic significance of changes in prostate-specific antigen in patients with metastasis prostate cancer after endocrine treatment. International Urology and Nephrology, 32, 659–663.

    Article  PubMed  CAS  Google Scholar 

  • Galasko, C.S. (1969) The detection of skeletal metastases from mammary cancer by gamma camera scintigraphy. British Journal of Surgery, 56, 757–764.

    Article  PubMed  CAS  Google Scholar 

  • Galasko, C.S. (1975) The value of scintigraphy in malignant disease. Cancer Treatment Reviews, 2, 225–272.

    Article  PubMed  CAS  Google Scholar 

  • Galasko, C.S. (1977) Detection of bone metastases. British Medical Journal, 1, 1537.

    Article  PubMed  CAS  Google Scholar 

  • Galasko, C.S. (1986) Skeletal metastases. Clinical Orthopaedics And Related Research, 18–30.

    Google Scholar 

  • Gulenchyn, K.Y. and Papoff, W. (1987) Technetium-99m MDP scintigraphy. An insensitive tool for the detection of bone marrow metastases. Clinical Nuclear Medicine, 12, 45–46.

    Article  PubMed  CAS  Google Scholar 

  • Harada, M., Iida, M., Yamaguchi, M. and Shida, K. (1992) Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases. Prostate Cancer and Bone Metastasis. Edited by J.P. Karr and H Yamanaka, Plenum Press, New York, 173–182.

    Chapter  Google Scholar 

  • Heaney, R.P. (1994) The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. Journal of Bone and Mineral Research, 9, 1515–1523.

    Article  PubMed  CAS  Google Scholar 

  • Ikeda, I., Miura, T. and Kondo, I. (1996) Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. British Journal of Cancer, 77, 102–106.

    CAS  Google Scholar 

  • Jacobs, S.C. (1983) Spread of prostatic cancer to bone. Urology, 21, 337–344.

    Article  PubMed  CAS  Google Scholar 

  • Jacobson, A.F., Stomper, P.C., Cronin, E.B. and Kaplan, W.D. (1990) Bone scans with one or two new abnormalities in cancer patients with no known metastases: reliability of interpretation of initial correlative radiographs. Radiology, 174, 503–507.

    PubMed  CAS  Google Scholar 

  • Jemal, A., Thomas, A., Murray, T. and Thun, M. (2002) Cancer statistics, 2002. CA-A Cancer Journal for Clinicians, 52, 23–47.

    Article  PubMed  Google Scholar 

  • Jorda, M., Morales, A., Ghorab, Z., Fernandez, G., Nadji, M. and Block, N. (2002) Her2 expression in prostatic cancer: a comparison with mammary carcinoma. Journal of Urology, 168, 1412–1414.

    Article  PubMed  Google Scholar 

  • Koutsilieris, M. (1993) Osteoblastic metastasis in advanced prostate cancer. Anticancer Research, 13, 443–449.

    PubMed  CAS  Google Scholar 

  • Krasnow, A.Z., Collier, B.D., Isitman, A.T., Hellman, R.S. and Ewey, D. (1988) Falsenegative bone imaging due to etidronate disodium therapy. Clinical Nuclear Medicine, 13, 264–267.

    Article  PubMed  CAS  Google Scholar 

  • Lamothe, F., Kovi, J., Heshmat, M.Y. and Green, E.J. (1986) Dissemination of prostatic carcinoma: an autopsy study. Journal of the National Medical Association, 78, 1083–1086.

    PubMed  CAS  Google Scholar 

  • Lara, P.N., Jr., Meyers, F.J., Gray, C.R., Edwards, R.G., Gumerlock, P.H., Kauderer, C., Tichauer, G., Twardowski, P., Doroshow, J.H. and Gandara, D.R. (2002) HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer, 94, 2584–2589.

    Article  PubMed  Google Scholar 

  • Leav, I., Lau, K.M., Adams, J.Y., McNeal, J.E., Taplin, M.E., Wang, J., Singh, H. and Ho, S.M. (2001) Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. American Journal of Pathology, 159, 79–92.

    Article  PubMed  CAS  Google Scholar 

  • Ligibel, J.A. and Winer, E.P. (2002) Trastuzumab/chemotherapy combinations in metastatic breast cancer. Seminars in Oncology, 29, 38–43.

    PubMed  CAS  Google Scholar 

  • Macro, M., Bouvard, G., Le Gangneux, E., Colin, T. and Loyau, G. (1995) Intravenous aminohydroxypropylidene bisphosphonate does not modify 99mTc-hydroxymethylene bisphosphonate bone scintigraphy. A prospective study. Revue du rhumatisme (English ed), 62, 99–104.

    PubMed  CAS  Google Scholar 

  • Maeda, H., Koizumi, M., Yoshimura, K., Yamauchi, T., Kawai, T. and Ogata, E. (1997) Correlation between bone metabolic markers and bone scan in prostatic cancer. Journal of Urology, 157, 539–543.

    Article  PubMed  CAS  Google Scholar 

  • Masarachia, P., Weinreb, M., Balena, R. and Rodan, G.A. (1996) Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone, 19, 281–290.

    Article  PubMed  CAS  Google Scholar 

  • McCarthy, E.F. (1997) Histopathologic correlates of a positive bone scan. Seminars in Nuclear Medicine, 27, 309–320.

    Article  PubMed  CAS  Google Scholar 

  • Mintz, R. and Smith, G.G. (1934) Autopsy findings in 100 cases of prostatic cancer. New England Journal of Medicine, 211, 481–487.

    Article  Google Scholar 

  • Morris, M.J., Reuter, V.E., Kelly, W.K., Slovin, S.F., Kenneson, K., Verbel, D., Osman, I. and Scher, H.I. (2002) HER-2 profiling and targeting in prostate carcinoma. Cancer, 94, 980–986.

    Article  PubMed  CAS  Google Scholar 

  • Murphy, G.P., Elgamal, A.A., Su, S.L., Bostwick, D.G. and Holmes, E.H. (1998) Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer, 83, 2259–2269.

    Article  PubMed  CAS  Google Scholar 

  • Osman, I., Scher, H.I., Drobnjak, M., Verbel, D., Morris, M., Agus, D., Ross, J.S. and Cordon-Cardo, C. (2001) HER-2/neu (pl85neu) protein expression in the natural or treated history of prostate cancer. Clinical Cancer Research, 7, 2643–2647.

    PubMed  CAS  Google Scholar 

  • Oyama, N., Akino, H., Kanamaru, H., Suzuki, Y., Muramoto, S., Yonekura, Y., Sadato, N., Yamamoto, K. and Okada, K. (2002) 1 lC-acetate PET imaging of prostate cancer. Journal of Nuclear Medicine, 43, 181–186.

    PubMed  CAS  Google Scholar 

  • Parfitt, A.M., Drezner, M.K., Glorieux, F.H., Kanis, J.A., Malluche, H., Meunier, P.J., Ott, S.M. and Recker, R.R. (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. Journal of Bone and Mineral Research, 2, 595–610.

    Article  PubMed  CAS  Google Scholar 

  • Paulson, D.F. (1980) Assessment of anatomic extent and biologic hazard of prostatic adenocarcinoma. Urology, 15, 537–541.

    Article  PubMed  CAS  Google Scholar 

  • Pecherstorfer, M., Schilling, T., Janisch, S., Woloszczuk, W., Baumgartner, G., Ziegler, R. and Ogris, E. (1993) Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. Journal of Nuclear Medicine, 34, 1039–1044.

    Google Scholar 

  • Percival, R.C., Urwin, G.H., Harris, S., Yates, A.J., Williams, J.L., Beneton, M. and Kanis, J.A. (1987a) Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. European Journal of Surgical Oncology, 13, 41–49.

    PubMed  CAS  Google Scholar 

  • Rana, A., Chisholm, G.D., Khan, M., Sekharjit, S.S., Merrick, M.V. and Elton, R.A. (1993) Patterns of bone metastasis and their prognostic significance in patients with carcinoma of the prostate. British Journal of Urology, 72, 933–936.

    Article  PubMed  CAS  Google Scholar 

  • Reuter, V.E. (1997) Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology, 49, 16–22.

    Article  PubMed  CAS  Google Scholar 

  • Rhodes, A., Jasani, B., Anderson, E., Dodson, A.R. and Balaton, A.J. (2002) Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. American Journal of Clinical Pathology, 118, 408–417.

    Article  PubMed  CAS  Google Scholar 

  • Rico, H., Uson, A., Hernandez, E.R., Prados, P., Paramo, P. and Cabranes, J.A. (1990) Hyperparathyroidism in metastases of prostatic carcinoma: a biochemical, hormonal and histomorphometric study. European Urology, 17, 35–39.

    PubMed  CAS  Google Scholar 

  • Rittenhouse, H.G., Finlay, J.A., Mikolajczyk, S.D. and Partin, A.W. (1998) Human Kallikrein 2 (hK2) and prostate specific antigen (PSA): Two clossely related, but distinct, kallikreins in the prostate. Critical Reviews in Clinical Laboratory Sciences, 35, 275–368.

    Article  PubMed  CAS  Google Scholar 

  • Ro, J.Y., Tetu, B., Ayala, A.G. and Ordonez, N.G. (1987) Small cell carcinoma of the prostate. II. Immunohistochemical and electron microscopic studies of 18 cases. Cancer, 59, 977–982.

    Article  PubMed  CAS  Google Scholar 

  • Roudier, M.P., Vesselle, H., True, L.D., Higano, C.S., Vessella, R. (2003) Concordance between bone histology and Technetium99 methylene diophosphonate bone scintigraphy in advanced prostate cancer patients with special reference to Pamidronate treatment. Clinical and Experimental Metastasis, in press.

    Google Scholar 

  • Roudier, M.P., True, L.D., Higano, C.S., Vesselle, H., Ellis W.J., Lange, P.H. and Vessella, R.L. (2002) Phenotypic heterogeneity of androgen-independent prostate cancer bone metastases. Human Pathology, (submitted).

    Google Scholar 

  • Rubin, M.A., Putzi, M., Mucci, N., Smith, D.C., Wojno, K., Korenchuk, S. and Pienta, K.J. (2000) Rapid (“warm” ) autopsy study for procurement of metastatic prostate cancer. Clinical Cancer Research, 6, 1038–1045.

    PubMed  CAS  Google Scholar 

  • Ryan, P.J., Gibson, T. and Fogelman, I. (1992) Bone scintigraphy following intravenous pamidronate for Paget’ s disease of bone. Journal of Nuclear Medicine, 33, 1589–1593.

    PubMed  CAS  Google Scholar 

  • Saad, F., Gleason, D.M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J.L., Vinholes, J.J., Goas, J.A. and Chen, B. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 94, 1458–1468.

    Article  PubMed  CAS  Google Scholar 

  • Saitoh, H., Hida, M., Shimbo, T., Nakamura, K., Yamagata, J. and Satoh, T. (1984) Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. Cancer, 54, 3078–3084.

    Article  PubMed  CAS  Google Scholar 

  • Sanchez, K.M., Sweeney, C.J., Mass, R., Koch, M.O., Eckert, G.J., Geary, W.A., Baldridge, L.A., Zhang, S., Eble, J.N. and Cheng, L. (2002) Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology. Cancer, 95, 1650–1655.

    Article  PubMed  Google Scholar 

  • Sandler, E.D., Parisi, M.T. and Hattner, R.S. (1991) Duration of etidronate effect demonstrated by serial bone scintigraphy. Journal of Nuclear Medicine, 32, 1782–1784.

    PubMed  CAS  Google Scholar 

  • Sebo, T.J., Cheville, J.C., Riehle, D.L., Lohse, C.M., Pankratz, V.S., Myers, R.P., Blute, M.L. and Zincke, H. (2002) Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. American Journal of Surgical Pathology, 26, 431–439.

    Article  PubMed  Google Scholar 

  • Shankar, G., Kelley, H., Samadzadeh, L., Lodge, A., Boynton, A., Papandreou, C., Logothetis, C., Belldegrun, A. and Elgamal, A. (2002) Induction of tumor antigen-specific immune responses in hormone-refractory priostate cancer patients treated with DCVaxPtostate in a Phase I/II clinical trial. Proceedings of the American Association for Cancer Research, 43, 144, #716.

    Google Scholar 

  • Signoretti, S., Montironi, R., Manola, J., Altimari, A., Tarn, C., Bubley, G., Balk, S., Thomas, G., Kaplan, I., Hlatky, L., Hahnfeldt, P., Kantoff, P. and Loda, M. (2000) Her-2-neu expression and progression toward androgen independence in human prostate cancer. Journal of the National Cancer Institute, 92, 1918–1925.

    Article  PubMed  CAS  Google Scholar 

  • Slamon, D.J. (1987) Proto-oncogenes and human cancers. New England Journal of Medicine, 317, 955–957.

    Article  PubMed  CAS  Google Scholar 

  • Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A. and McGuire, W.L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science, 235, 177–182.

    Article  PubMed  CAS  Google Scholar 

  • Spigel, D.R. and Burstein, HJ. (2002) HER2 overexpressing metastatic breast cancer. Current Treatment Options in Oncology, 3, 163–174.

    Article  PubMed  Google Scholar 

  • Stein, B.S., Vangore, S. and Petersen, R.O. (1984) Immunoperoxidase localization of prostatic antigens. Comparison of primary and metastatic sites. Urology, 24, 146–152.

    Article  PubMed  CAS  Google Scholar 

  • Suzuki, T., Shimizu, T., Kurokawa, K., Jimbo, H., Sato, J. and Yamanaka, H. (1994) Pattern of prostate cancer metastasis to the vertebral column. Prostate, 25, 141–146.

    Article  PubMed  CAS  Google Scholar 

  • Takeuchi, S.I., Arai, K., Saitoh, H., Yoshida, K.I. and Miura, M. (1996) Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. Journal of Urology, 156, 1691–1695.

    Article  PubMed  CAS  Google Scholar 

  • Taube, T., Beneton, M.N., Williams, J.L., McCloskey, E.V. and Kanis, J.A. (1993) Distinction between focally accelerated bone formation and osteomalacia in carcinoma of prostate metastasised to bone. British Journal of Urology, 72, 98–103.

    Article  PubMed  CAS  Google Scholar 

  • Taube, T., Elomaa, I., Blomqvist, C., Beneton, M.N. and Kanis, J.A. (1994) Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone, 15, 161–166.

    Article  PubMed  CAS  Google Scholar 

  • Thompson, H. (1854) Comments. Transactions of the Pathology Society of London, 5, 204.

    Google Scholar 

  • Van der Kwast, T.H. and Tetu, B. (1996) Androgen receptors in untreated and treated prostatic intraepithelial neoplasia. European Urology, 30, 265–268.

    PubMed  Google Scholar 

  • Watt, I. and Hill, P. (1981) Effects of acute administration of ethane hydroxydiphosphonate (EHDP) on skeletal scintigraphy with technetium-99m methylene diphosphonic acid (TcMDP) in the rat. British Journal of Radiology, 54, 592–596.

    Article  PubMed  CAS  Google Scholar 

  • Weinstein, M.H., Partin, A.W., Veltri, R.W. and Epstein, J.I. (1996) Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Human Pathology, 27, 683–687.

    Article  PubMed  CAS  Google Scholar 

  • Whitmore, Jr.W.F. (1990) Natural history of low-stage prostatic cancer and the impact of early detection. Urologic Clinics of North America, 17, 689–697.

    PubMed  Google Scholar 

  • Yao, D., Trabulsi, E.J., Kostakoglu, L., Vallabhajosula, S., Joyce, M.A., Nanus, D.M., Milowsky, M., Liu, H. and Goldsmith, S.J. (2002) The utility of monoclonal antibodies in the imaging of prostate cancer. Seminars in Urologic Oncology, 20, 211–218.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Washington Medical Center, Seattle, WA, USA

    Martine P. Roudier, Eva Corey & Robert L. Vessella

  2. Department of Pathology, University of Washington Medical Center, Seattle, WA, USA

    Lawrence D. True

  3. Department of Medicine (Oncology), University of Washington Medical Center, Seattle, WA, USA

    Celestia S. Hiagno

  4. Department of Medicine (Metabolism), University of Washington Medical Center, Seattle, WA, USA

    Susan M. Ott

  5. VA Puget Sound Health Care System, Research Service, Seattle, WA, USA

    Robert L. Vessella

Authors
  1. Martine P. Roudier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eva Corey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lawrence D. True
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Celestia S. Hiagno
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Susan M. Ott
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert L. Vessella
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Michigan Comprehensive Cancer Center University of Michigan School of Medicine, University of Michigan, Ann Arbor, Michigan, USA

    Evan T. Keller DVM, PhD (Associate Professor of Urology, Comparative Medicine and Pathology) (Associate Professor of Urology, Comparative Medicine and Pathology)

  2. Emory University School of Medicine, Emory University, Atlanta, Georgia, USA

    Leland W. K. Chung PhD (Professor of Urology, Hematology/Oncology, Biochemistry and the Winship Cancer Institute) (Professor of Urology, Hematology/Oncology, Biochemistry and the Winship Cancer Institute)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Roudier, M.P., Corey, E., True, L.D., Hiagno, C.S., Ott, S.M., Vessella, R.L. (2004). Histological, Immunophenotypic and Histomorphometric Characterization of Prostate Cancer Bone Metastases. In: Keller, E.T., Chung, L.W.K. (eds) The Biology of Skeletal Metastases. Cancer Treatment and Research, vol 118. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9129-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9129-4_13

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4803-0

  • Online ISBN: 978-1-4419-9129-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation